BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:EPI-326 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of EPI-326\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07462377-2475@assetmemo.bio
DTSTAMP:20261121T005847Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:EPI-326: Phase 1 readout est. (NCT07462377)
DESCRIPTION:EPI-326\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Phase
  1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC\nEstimated primary comp
 letion: July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ep
 i-326#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07462377
URL:https://assetmemo.bio/drug/epi-326#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
